P. Duvaldestin, K. Kuizenga, V. Saldien, C. Claudius, F. Servin, J. Klein, B. Debaene and M. Heeringa, “A Randomized, Dose-Response Study of Sugam-Madex Given for the Reversal of Deep Rocuronium or Vecuronium Induced Neuromuscular Blockade under Sevourane Anesthesia,” Anesthesia and Analgesia, Vol. 110, No. 1, 2010, pp. 74-82. doi:10.1213/ANE.0b013e3181c3be3c

has been cited by the following article:

• TITLE: Successful Use of Sugammadex in a Myasthenic Patient Case Report

  AUTHORS: Silvia Kangassu Rios, Daiana Gomes, Marcos Lopes De Miranda, Carlos Frederico La Cava, Carlos Darcy Bersot

  KEYWORDS: Sugammadex; Myasthenia Gravis; Rocuronium; Neuromuscular Monitoring; Anesthesia

  JOURNAL NAME: Open Journal of Anesthesiology, Vol.3 No.1, January 31, 2013

  ABSTRACT: The Myasthenia gravis (MG) is an autoimmune disease that affects neuromuscular transmission and leads to a large variation of sensibility on depolarizing and nondepolarizing neuromuscular blocking drugs. Sugammadex is a new drug with the capability to successfully revert the nondepolarizing neuromuscular blocking. This case report will show a patient with MG that was scheduled for thymectomy, with the objective to use sugammadex to reverse a rocuronium induced deep level of neuromuscular block and observing the safe use of sugammadex without complications.